Macrovascular Risk Equations Based on the CANVAS Program
- 13 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 39 (4), 447-461
- https://doi.org/10.1007/s40273-021-01001-0
Abstract
Background Widely used risk equations for cardiovascular outcomes for individuals with type 2 diabetes mellitus (T2DM) have been incapable of predicting cardioprotective effects observed in recent cardiovascular outcomes trials (CVOTs) involving individuals with T2DM at high risk for or with established cardiovascular disease (CVD). Objective We developed cardiovascular and mortality risk equations using patient-level data from the CANVAS (CANagliflozin cardioVascular Assessment Study) Program to address this shortcoming. Methods Data from 10,142 patients with T2DM at high risk for or with established CVD, randomized to canagliflozin + standard of care (SoC) or SoC alone and followed for a mean duration of 3.6 years in the CANVAS Program were used to derive parametric risk equations for myocardial infarction (MI), stroke, hospitalization for heart failure (HHF), and death. Accumulated knowledge from the widely used UKPDS-OM2 (United Kingdom Prospective Diabetes Study Outcomes Model 2) was leveraged, and any departures in parameterization were limited to those necessary to provide adequate goodness of fit. Candidate explanatory covariates were selected using only the placebo arm to minimize confounding effects. Internal validation was performed separately by study treatment arm. Results UKPDS-OM2 predicted CANVAS Program outcomes poorly. Recalibrating UKPDS-OM2 intercepts improved calibration in some cases. Refitting the coefficients but otherwise preserving the UKPDS-OM2 structure improved the fit substantially, which was sufficient for stroke and death. For MI, reselecting UKPDS-OM2 covariates and functional form proved sufficient. For HHF, selection from a broad set of candidate covariates and inclusion of a canagliflozin indicator was required. Conclusion These risk equations address some of the limitations of widely used risk equations, such as the UKPDS-OM2, for modeling cardioprotective treatments for individuals with T2DM and high cardiovascular risk, including derivation from overly healthy patients treated with agents that lack cardioprotection and have been described as reflecting a different therapeutic era. Future work is needed to examine external validity.Funding Information
- Janssen Global Services, LLC
This publication has 54 references indexed in Scilit:
- Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic reviewHeart, 2011
- Strong Rules for Discarding Predictors in Lasso-Type ProblemsJournal of the Royal Statistical Society Series B: Statistical Methodology, 2011
- Confounding of Indirect Effects: A Sensitivity Analysis Exploring the Range of Bias Due to a Cause Common to Both the Mediator and the OutcomeAmerican Journal of Epidemiology, 2011
- Prediction of Coronary Heart Disease Risk in a General, Pre-Diabetic, and Diabetic Population During 10 Years of Follow-up: Accuracy of the Framingham, SCORE, and UKPDS Risk FunctionsDiabetes Care, 2009
- ForewordAmerican Journal of Kidney Diseases, 2007
- KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney DiseaseAmerican Journal of Kidney Diseases, 2007
- Regularization and Variable Selection Via the Elastic NetJournal of the Royal Statistical Society Series B: Statistical Methodology, 2005
- Guidelines for Computer Modeling of Diabetes and Its ComplicationsDiabetes Care, 2004
- UKPDS 60Stroke, 2002
- Cardiovascular disease risk profilesAmerican Heart Journal, 1991